Autoimmune retinopathy historical perspective: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Autoimmune retinopathy}} | {{Autoimmune retinopathy}} | ||
{{CMG}} | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [https://www.wikidoc.org/index.php/User:Hassan_M M. Hassan, M.B.B.S] | ||
==Overview== | ==Overview== | ||
Revision as of 05:19, 17 July 2022
|
Autoimmune retinopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Autoimmune retinopathy historical perspective On the Web |
|
American Roentgen Ray Society Images of Autoimmune retinopathy historical perspective |
|
Risk calculators and risk factors for Autoimmune retinopathy historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
Historical Perspective
In 1976, the first cases of cancer associated retinopathy (CAR) were observed in three female patients with bronchial carcinoma who developed vision loss with photoreceptor (rods and cones) degeneration.
In 1987, 23-kDa retinal antigen, recoverin, targeted by antibodies in the serum of CAR patients was identified by Thirkill and colleague.
In 1997, the first case of autoimmune retinopathy (AIR) was reported in the absence of malignancy with clinical features similar to CAR. Since then, hundreds of cases of paraneoplastic AIR, and non-paraneoplastic AIR have been reported. [1]